ZUMA-3: CAR T Therapy for Adult Patients With ALL - Episode 5

The ZUMA-3 Trial: Clinical Endpoints


Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.